Engineering Papers⌕ Search

Engineering topics

Wang, Ping

Publications and source records attributed to Wang, Ping.

At least 91 records · Page 5
All sourcesNASA NTRSDOE OSTI
DOE OSTI2018

CtBP represses Dpp signaling as a dimer

Highlights: • Ectopic expression of CtBP causes a disrupted wing vein pattern. • CtBP causes a decreased pMad level. • CtBP requires dimerization to repress Dpp signaling pathway. C-terminal binding protein (CtBP) is a highly conserved transcriptional co-repressor in animal development and human diseases. In Drosophila, CtBP is critical for fly development and is thought to exert its repressive roles in many signaling pathways including Dpp/BMP pathway. Here we provide evidence that although wild type CtBP negatively and dominantly influences Dpp signaling in fly presumptive wings, mutant CtBP unable to form dimer does not, indicating that dimerization is required for the repression role of CtBP in Dpp signaling in vivo.

60 APPLIED LIFE SCIENCES↗
DOE OSTI2018

Dual Allosteric Inhibition of SHP2 Phosphatase

SHP2 is a cytoplasmic protein tyrosine phosphatase encoded by the PTPN11 gene and is involved in cell proliferation, differentiation, and survival. Recently, we reported an allosteric mechanism of inhibition that stabilizes the auto-inhibited conformation of SHP2. SHP099 (1) was identified and characterized as a moderately potent, orally bioavailable, allosteric small molecule inhibitor, which binds to a tunnel-like pocket formed by the confluence of three domains of SHP2. In this report, we describe further screening strategies that enabled the identification of a second, distinct small molecule allosteric site. SHP244 (2) was identified as a weak inhibitor of SHP2 with modest thermal stabilization of the enzyme. X-ray crystallography revealed that 2 binds and stabilizes the inactive, closed conformation of SHP2, at a distinct, previously unexplored binding site—a cleft formed at the interface of the N-terminal SH2 and PTP domains. Derivatization of 2 using structure-based design resulted in an increase in SHP2 thermal stabilization, biochemical inhibition, and subsequent MAPK pathway modulation. Downregulation of DUSP6 mRNA, a downstream MAPK pathway marker, was observed in KYSE-520 cancer cells. Remarkably, simultaneous occupation of both allosteric sites by 1 and 2 was possible, as characterized by cooperative biochemical inhibition experiments and X-ray crystallography. Combining an allosteric site 1 inhibitor with an allosteric site 2 inhibitor led to enhanced pharmacological pathway inhibition in cells. This work illustrates a rare example of dual allosteric targeted protein inhibition, demonstrates screening methodology and tactics to identify allosteric inhibitors, and enables further interrogation of SHP2 in cancer and related pathologies.

37 INORGANIC, ORGANIC, PHYSICAL, AND ANALYTICAL CH↗
DOE OSTI2017

Impact of Thermal Pretreatment Temperatures on Woody Biomass Chemical Composition, Physical Properties and Microstructure

Thermal pretreatment of biomass by torrefaction and low temperature pyrolysis has the potential for generating high quality and more suitable fuels. To utilize a model to describe the complex and dynamic changes taking place during these two treatments for process design, optimization and scale-up, detailed data is needed on the property evolution during treatment of well-defined individual biomass particles. The objectives of this study are to investigate the influence of thermal pretreatment temperatures on wood biomass biochemical compositions, physical properties and microstructure. Wild cherry wood was selected as a model biomass and prepared for this study. The well-defined wood particle samples were consecutively heated at 220, 260, 300, 350, 450 and 550 °C for 0.5 h under nitrogen. Untreated and treated samples were characterized for biochemical composition changes (cellulose, hemicellulose, and lignin) by thermogravimetric analyzer (TGA), physical properties (color, dimensions, weight, density and grindablity), chemical property (proximate analysis and heating value) and microstructural changes by scanning electron microscopy (SEM). Hemicellulose was mostly decomposed in the samples treated at 260 and 300 °C and resulted in the cell walls weakening resulting in improved grindability. The dimensions of the wood were reduced in all directions and shrinkage increased with increased treatment temperature and weight loss. With increased treatment temperature, losses of weight and volume increased and bulk density decreased. The low temperature pyrolyzed wood samples improved solid fuel property with high fuel ratio, which are close to lignite/bituminous coal. Morphology of the wood remained intact through the treatment range but the cell walls were thinner. Lastly, these results will improve the understanding of the property changes of the biomass during pretreatment and will help to develop models for process simulation and potential application of the treated biomass.

09 BIOMASS FUELS↗
DOE OSTI2017

Three-Dimensional Design Simulations of a High-Energy Density Reshock Experiment at the National Ignition Facility

We present here simulations of a new experimental platform at the National Ignition Facility (NIF) for studying the hydrodynamic instability growth of a high-energy density (HED) fluid interface that undergoes multiple shocks, i.e., is “reshocked.” In these experiments, indirect-drive laser cavities drive strong shocks through an initially solid, planar interface between a high-density plastic and low-density foam, in either one or both directions. The first shock turns the system into an unstable fluid interface with the premachined initial condition that then grows via the Richtmyer–Meshkov and Rayleigh–Taylor instabilities. Backlit X-ray imaging is used to visualize the instability growth at different times. Our main result is that this new HED reshock platform is established and that the initial data confirm the experiment operates in a hydrodynamic regime similar to what simulations predict. The simulations also reveal new types of edge effects that can disturb the experiment at late times and suggest ways to mitigate them.

42 ENGINEERING↗
DOE OSTI2017

Treatment of Parkinson's disease in rats by Nrf2 transfection using MRI-guided focused ultrasound delivery of nanomicrobubbles

Parkinson's disease (PD) is a very common neurological disorder. However, effective therapy is lacking. Although the blood-brain-barrier (BBB) protects the brain, it prevents the delivery of about 90% of drugs and nucleotides into the brain, thereby hindering the development of gene therapy for PD. Magnetic resonance imaging (MRI)-guided focused ultrasound delivery of microbubbles enhances the delivery of gene therapy vectors across the BBB and improves transfection efficiency. In the present study, we delivered nuclear factor E2-related factor 2 (Nrf2, NFE2L2) contained in nanomicrobubbles into the substantia nigra of PD rats by MRI-guided focused ultrasound, and we examined the effect of Nrf2 over-expression in this animal model of PD. The rat model of PD was established by injecting 6-OHDA in the right substantia nigra stereotactically. Plasmids (pDC315 or pDC315/Nrf2) were loaded onto nanomicrobubbles, and then injected through the tail vein with the assistance of MRI-guided focused ultrasound. MRI-guided focused ultrasound delivery of nanomicrobubbles increased gene transfection efficiency. Furthermore, Nrf2 gene transfection reduced reactive oxygen species levels, thereby protecting neurons in the target region. - Highlights: • MRI-guided focused ultrasound enhances gene transfection into the brain of rats. • Increased Nrf2 expression protects neurons in the rat model of PD. • Nrf2 protects neurons in PD by inhibiting ROS production.

60 APPLIED LIFE SCIENCES↗
DOE OSTI2016

Structural Basis for Inhibitor-Induced Aggregation of HIV Integrase

The allosteric inhibitors of integrase (termed ALLINIs) interfere with HIV replication by binding to the viral-encoded integrase (IN) protein. Surprisingly, ALLINIs interfere not with DNA integration but with viral particle assembly late during HIV replication. To investigate the ALLINI inhibitory mechanism, we crystallized full-length HIV-1 IN bound to the ALLINI GSK1264 and determined the structure of the complex at 4.4 Å resolution. The structure shows GSK1264 buried between the IN C-terminal domain (CTD) and the catalytic core domain. In the crystal lattice, the interacting domains are contributed by two different dimers so that IN forms an open polymer mediated by inhibitor-bridged contacts; the N-terminal domains do not participate and are structurally disordered. Engineered amino acid substitutions at the inhibitor interface blocked ALLINI-induced multimerization. HIV escape mutants with reduced sensitivity to ALLINIs commonly altered amino acids at or near the inhibitor-bound interface, and these substitutions also diminished IN multimerization. We propose that ALLINIs inhibit particle assembly by stimulating inappropriate polymerization of IN via interactions between the catalytic core domain and the CTD and that understanding the interface involved offers new routes to inhibitor optimization.

59 BASIC BIOLOGICAL SCIENCES↗
DOE OSTI2016

Positive temperature coefficient of photovoltaic efficiency in solar cells based on InGaN/GaN MQWs

We report a 23.4% improvement of conversion efficiency in solar cells based on InGaN/GaN multiple quantum wells by using a patterned sapphire substrate in the fabrication process. The efficiency enhancement is due to the improvement of the crystalline quality, as proven by the reduction of the threading dislocation density. More importantly, the better crystalline quality leads to a positive photovoltaic efficiency temperature coefficient up to 423 K, which shows the property and advantage of wide gap semiconductors like InGaN, signifying the potential of III-nitride based solar cells for high temperature and concentrating solar power applications.

71 CLASSICAL AND QUANTUM MECHANICS, GENERAL PHYSIC↗
DOE OSTI2016

Structural Basis for Cooperative Function of Mettl3 and Mettl14 Methyltransferases

N 6 -methyladenosine (m 6 A) is a prevalent, reversible chemical modification of functional RNAs and is important for central events in biology. The core m 6 A writers are Mettl3 and Mettl14, which both contain methyltransferase domains. How Mettl3 and Mettl14 cooperate to catalyze methylation of adenosines has remained elusive. Here, we present crystal structures of the complex of Mettl3/Mettl14 methyltransferase domains in apo form as well as with bound S-adenosylmethionine (SAM) or S-adenosylhomocysteine (SAH) in the catalytic site. We determine that the heterodimeric complex of methyltransferase domains, combined with CCCH motifs, constitutes the minimally required regions for creating m 6 A modifications in vitro. We also show that Mettl3 is the catalytically active subunit, while Mettl14 plays a structural role critical for substrate recognition. Our model provides a molecular explanation for why certain mutations of Mettl3 and Mettl14 lead to impaired function of the methyltransferase complex.

37 INORGANIC, ORGANIC, PHYSICAL, AND ANALYTICAL CH↗
DOE OSTI2016

Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases

The non-receptor protein tyrosine phosphatase SHP2, encoded by PTPN11, has an important role in signal transduction downstream of growth factor receptor signalling and was the first reported oncogenic tyrosine phosphatase1. Activating mutations of SHP2 have been associated with developmental pathologies such as Noonan syndrome and are found in multiple cancer types, including leukaemia, lung and breast cancer and neuroblastoma1, 2, 3, 4, 5. SHP2 is ubiquitously expressed and regulates cell survival and proliferation primarily through activation of the RAS–ERK signalling pathway2, 3. It is also a key mediator of the programmed cell death 1 (PD-1) and B- and T-lymphocyte attenuator (BTLA) immune checkpoint pathways6, 7. Reduction of SHP2 activity suppresses tumour cell growth and is a potential target of cancer therapy8, 9. Here we report the discovery of a highly potent (IC50 = 0.071 μM), selective and orally bioavailable small-molecule SHP2 inhibitor, SHP099, that stabilizes SHP2 in an auto-inhibited conformation. SHP099 concurrently binds to the interface of the N-terminal SH2, C-terminal SH2, and protein tyrosine phosphatase domains, thus inhibiting SHP2 activity through an allosteric mechanism. SHP099 suppresses RAS–ERK signalling to inhibit the proliferation of receptor-tyrosine-kinase-driven human cancer cells in vitro and is efficacious in mouse tumour xenograft models. Together, these data demonstrate that pharmacological inhibition of SHP2 is a valid therapeutic approach for the treatment of cancers.

59 BASIC BIOLOGICAL SCIENCES↗
DOE OSTI2016

Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor

SHP2 is a nonreceptor protein tyrosine phosphatase (PTP) encoded by the PTPN11 gene involved in cell growth and differentiation via the MAPK signaling pathway. SHP2 also purportedly plays an important role in the programmed cell death pathway (PD-1/PD-L1). Because it is an oncoprotein associated with multiple cancer-related diseases, as well as a potential immunomodulator, controlling SHP2 activity is of significant therapeutic interest. Recently in our laboratories, a small molecule inhibitor of SHP2 was identified as an allosteric modulator that stabilizes the autoinhibited conformation of SHP2. A high throughput screen was performed to identify progressable chemical matter, and X-ray crystallography revealed the location of binding in a previously undisclosed allosteric binding pocket. Structure-based drug design was employed to optimize for SHP2 inhibition, and several new protein–ligand interactions were characterized. Furthermore, these studies culminated in the discovery of 6-(4-amino-4-methylpiperidin-1-yl)-3-(2,3-dichlorophenyl)pyrazin-2-amine (SHP099, 1), a potent, selective, orally bioavailable, and efficacious SHP2 inhibitor.

37 INORGANIC, ORGANIC, PHYSICAL, AND ANALYTICAL CH↗